Form 4: Tarsus Pharmaceuticals Director Trades Common Stock

Andrew D. Goldberg, a Director at Tarsus Pharmaceuticals, Inc., reported a transaction involving the acquisition of common stock through the settlement of vested Restricted Stock Units.

Summary

• Andrew D. Goldberg, a Director of Tarsus Pharmaceuticals, Inc. (TARS), reported a transaction on June 12, 2026.
• The transaction involved the acquisition of 2,954 shares of common stock.
• These shares were acquired through the settlement of vested Restricted Stock Units (RSUs).
• Following this transaction, Mr. Goldberg beneficially owns 19,654 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine insider transaction related to the settlement of vested equity awards, rather than a significant event impacting company performance or strategy.

Positives

• Director Andrew D. Goldberg acquired additional shares of common stock, indicating continued investment or alignment with the company's performance.
• The acquisition of 2,954 shares through vested RSUs suggests that performance or service conditions tied to these units have been met.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and reflect individual director actions rather than broad company performance or strategic shifts. Such filings are crucial for transparency in the pharmaceutical sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding director's equity holdings and potential alignment of interests.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Tarsus Pharmaceuticals, TARS, Director, Stock Transaction, Restricted Stock Units, Common Stock